{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:58:19Z","timestamp":1793350699029,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T00:00:00Z","timestamp":1695945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.msard.2023.105037","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T07:45:12Z","timestamp":1696059912000},"page":"105037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2200-1525","authenticated-orcid":false,"given":"Brit Ellen","family":"R\u00f8d","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Wergeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"Bj\u00f8rnevik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trygve","family":"Holm\u00f8y","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elling","family":"Ulvestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro","family":"Nj\u00f8lstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2023.105037_bib0001","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: more than 50 years old and still providing surprises","volume":"16","author":"Young","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.msard.2023.105037_bib0002","article-title":"Epstein-Barr virus and systemic autoimmune diseases","volume":"11","author":"Houen","year":"2020","journal-title":"Front Immunol."},{"key":"10.1016\/j.msard.2023.105037_bib0003","doi-asserted-by":"crossref","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","author":"Bjornevik","year":"2022","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.msard.2023.105037_bib0004","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","article-title":"Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study","volume":"286","author":"Ascherio","year":"2001","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.msard.2023.105037_bib0005","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1212\/01.WNL.0000130496.51156.D7","article-title":"An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study","volume":"62","author":"Sundstr\u00f6m","year":"2004","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.msard.2023.105037_bib0006","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1001\/jama.293.20.2496","article-title":"Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis","volume":"293","author":"Levin","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2023.105037_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded b cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","author":"Lanz","year":"2022","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.msard.2023.105037_bib0008","doi-asserted-by":"crossref","first-page":"eadg3032","DOI":"10.1126\/sciadv.adg3032","article-title":"Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis","volume":"9","author":"Thomas","year":"2023","journal-title":"Sci. Adv."},{"issue":"34","key":"10.1016\/j.msard.2023.105037_bib0009","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"116","author":"Tengvall","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"70","key":"10.1016\/j.msard.2023.105037_bib0010","doi-asserted-by":"crossref","first-page":"eabo7799","DOI":"10.1126\/sciimmunol.abo7799","article-title":"Epstein-Barr virus as a driver of multiple sclerosis","volume":"7","author":"Sollid","year":"2022","journal-title":"Sci. Immunol."},{"issue":"19","key":"10.1016\/j.msard.2023.105037_bib0011","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1212\/WNL.0000000000002099","article-title":"No association of multiple sclerosis activity and progression with EBV or tobacco use in benefit","volume":"85","author":"Munger","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2023.105037_bib0012","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/WNL.0b013e3181aa29fe","article-title":"Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI","volume":"73","author":"Farrell","year":"2009","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.msard.2023.105037_bib0013","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1177\/1352458514533843","article-title":"Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis","volume":"20","author":"Kvistad","year":"2014","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2023.105037_bib0014","doi-asserted-by":"crossref","first-page":"e53996","DOI":"10.1371\/journal.pone.0053996","article-title":"Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study","volume":"8","author":"Horakova","year":"2013","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.msard.2023.105037_bib0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ana.21886","article-title":"Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis","volume":"67","author":"L\u00fcnemann","year":"2010","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2023.105037_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175279","article-title":"Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis","volume":"12","author":"Gie\u00df","year":"2017","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.msard.2023.105037_bib0017","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.105037_bib0018","article-title":"Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis - A cohort study","volume":"7","author":"Torgauten","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2023.105037_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103678","article-title":"The elimination of circulating Epstein-Barr virus infected B cells underlies anti-CD20 monoclonal antibody activity in multiple sclerosis: a hypothesis","volume":"59","author":"Berger","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2023.105037_bib0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2023.105037_bib0021","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.biologicals.2016.04.010","article-title":"A collaborative study to establish the 1st WHO International Standard for Epstein-Barr virus for nucleic acid amplification techniques","volume":"44","author":"Fryer","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.msard.2023.105037_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104497","article-title":"The concentrations of antibodies to Epstein-Barr virus decrease during ocrelizumab treatment","volume":"70","author":"Pham","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105037_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104094","article-title":"Effect of ocrelizumab on leptomeningeal inflammation and humoral response to Epstein-Barr virus in multiple sclerosis. A pilot study","volume":"67","author":"Zivadinov","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2023.105037_bib0024","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/1352458520907901","article-title":"Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors","volume":"26","author":"Jacobs","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105037_bib0025","article-title":"HLA-DRB1\u00d71501 influences long-term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis","author":"Brownlee","year":"2022","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2023.105037_bib0026","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2023.105037_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/v15030656","article-title":"Virological markers in Epstein-Barr virus-associated diseases","volume":"15","author":"Lupo","year":"2023","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.msard.2023.105037_bib0028","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1468-1331.2004.00871.x","article-title":"Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis","volume":"11","author":"Wagner","year":"2004","journal-title":"Eur J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.105037_bib0029","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/589714","article-title":"Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells","volume":"198","author":"Hoover","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.msard.2023.105037_bib0030","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1128\/JVI.73.2.1555-1564.1999","article-title":"X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus","volume":"73","author":"Faulkner","year":"1999","journal-title":"J. Virol."},{"issue":"21","key":"10.1016\/j.msard.2023.105037_bib0031","doi-asserted-by":"crossref","first-page":"11139","DOI":"10.1128\/JVI.76.21.11139-11142.2002","article-title":"Evidence for early infection of nonneoplastic natural killer cells by Epstein-Barr virus","volume":"76","author":"Trempat","year":"2002","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.msard.2023.105037_bib0032","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200084","article-title":"Ocrelizumab impairs the phenotype and function of memory CD8(+) T Cells: a 1-year longitudinal study in patients with multiple sclerosis","volume":"10","author":"Mathias","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2023.105037_bib0033","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1352458513494489","article-title":"Cytomegalovirus seropositivity is negatively associated with multiple sclerosis","volume":"20","author":"Sundqvist","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.105037_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103282","article-title":"The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment","volume":"56","author":"Pham","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2023.105037_bib0035","article-title":"Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis","volume":"219","author":"Schneider-Hohendorf","year":"2022","journal-title":"J. Exp. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T16:12:30Z","timestamp":1727453550000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823005382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":35,"alternative-id":["S2211034823005382"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105037","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105037"}}